Abstract

The hepatocyte nuclear factor 4 gamma (HNF4G), a member of orphan nuclear receptors, is up-regulated and functions as an oncoprotein in bladder cancer. In the present study, we observed that HNF4G expression was elevated in lung cancer tissues as compared to adjacent normal lung tissues. The expression of HNF4G protein was correlated with the tumor size and the prognosis of patients. Transfection with a small interference RNA (siRNA) targeting HNF4G in two lung cancer cell lines (H358 and H292 cells) significantly inhibited cell proliferation via arresting cells at G1 phase and inducing cell apoptosis. In addition, HNF4G siRNA reduced cell proliferation in a xenograft tumor-bearing model. Moreover, A549 cells, which had relative lower level of HNF4G, were ectopic expressed with HNF4G and treated with an AKT inhibitor (MK-2206). MK-2206 exposure not only attenuated the promoting effects of HNF4G overexpression on cell proliferation and cell cycle progression, but also suppressed the inhibitory effects of HNF4G overexpression on cell apoptosis. These data suggested that AKT signaling pathway was a potential upstream mediator of HNF4G. Collectively, our data indicate that HNF4G exerts as an oncogenic role in lung cancer by promoting cell proliferation and that HNF4G expression is a potential prognosis factor for lung cancer.

Highlights

  • Lung cancer is one of the most lethal human malignancies with over 1.2 million death each year worldwide

  • By analyzing the expression data of 488 lung cancer specimens and 58 normal lung specimens from The Cancer Genome Atlas project (TCGA, https://tcga-data. nci.nih.gov/tcga/), we found that hepatocyte nuclear factor 4 gamma (HNF4G) expression was significantly higher in lung cancer tissues (P < 0.0001; Figure 1A)

  • We investigated the expression and biological functions of a nuclear receptor, HNF4G in lung cancer

Read more

Summary

Introduction

Lung cancer is one of the most lethal human malignancies with over 1.2 million death each year worldwide. Emerging evidence has demonstrated the alteration of components of several signaling pathways, such as epidermal growth factor receptor (EGFR) [2, 3], PI3K/ AKT [4, 5], p53 [6, 7], p16INK4/cyclin D1/Rb pathways [8, 9], in lung cancer. Such alterations tend to drive cells to proliferation and escape from apoptosis.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call